Drug Profile
Nerve growth factor - Staidson Beijing BioPharmaceuticals
Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Staidson Beijing BioPharmaceuticals
- Class Eye disorder therapies; Nerve growth factors
- Mechanism of Action Neuron stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Optic nerve disorders
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Optic nerve disorders in China (Parenteral) prior to September 2023 (Staidson Beijing BioPharmaceuticals pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Optic-nerve-disorders in China (Parenteral)
- 07 Jul 2016 Preclinical trials in Optic nerve disorders in China (Parenteral)